SIMULATIONS PLUS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.02 USD | -2.18% |
|
-20.01% | -13.09% |
| 07-03 | US Equity Markets End Mixed Wednesday as Probability of Interest Rate Cut Rises | MT |
| 07-03 | Sector Update: Health Care Stocks Fall in Afternoon Trading | MT |
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.
Calendar
2024-10-22
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
39.89
USD
Average target price
60.33
USD
Spread / Average Target
+51.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.09% | 798M | |
| -4.84% | 29.31B | |
| +36.58% | 9.09B | |
| +32.70% | 4.4B | |
| -39.51% | 2.26B | |
| -7.15% | 1.6B | |
| -29.44% | 1.23B | |
| -43.35% | 966M | |
| -48.40% | 699M | |
| -29.48% | 595M |
- Stock Market
- Equities
- SLP Stock
- News Simulations Plus, Inc.
- Earnings Flash (SLP) SIMULATIONS PLUS Reports Q3 Adjusted EPS $0.19, vs. Street Est of $0.16
